Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~* Has a diagnosis of T2DM.~* Has HbA1c of 8.0% to 12.0%, inclusive, at Visit 1 and Visit 2.~* Treated with a stable dose of metformin ≥1500 mg/day for at least 2 months prior to Screening.~Exclusion criteria~* FPG ≥280 mg/dL (15.6 mmol/L).~* Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)~* Clinically significant abnormal free T4 values or patients needing initiation or adjustment of thyroid treatment according to the investigator.~* Abnormal thyroid stimulating hormone (TSH) value at Screening will be further evaluated by free T4.Patients with clinically significant abnormal free T4 values will be excluded.~* Known active proliferative retinopathy.~* History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1~* History or presence of inflammatory bowel disease or other severe GI diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis.~* History of gastric bypass surgery or gastric banding surgery, or either procedure is planned during the time period of the study. Current use of gastric balloons is also excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg (Type: EXPERIMENTAL): None
- Exenatide Once Weekly 2 mg Alone (Type: EXPERIMENTAL): None
- Dapagliflozin Once Daily 10 mg Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).